The molecular rationale for therapeutic targeting of glutamine metabolism in pulmonary hypertension.

ABSTRACT:

Introduction

Pulmonary hypertension (PH) is a deadly enigmatic disease with increasing prevalence. Cellular pathologic hallmarks of PH are driven at least partly by metabolic rewiring, but details are just emerging. The discovery that vascular matrix stiffening can mechanically activate the glutaminase (GLS) enzyme and serve as a pathogenic mechanism of PH has advanced our understanding of the complex role of glutamine in PH. It has also offered a novel therapeutic target for development as a next-generation drug for this disease. Area covered: This review discusses the cellular contribution of glutamine metabolism to PH together with the possible therapeutic application of pharmacologic GLS inhibitors in this disease. Expert opinion: Despite advances in our understanding of glutam

SUBMITTER: Bertero T 

PROVIDER: S-EPMC6625322 | biostudies-literature | 2019 Jun

REPOSITORIES: biostudies-literature